Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Meta-Analysis Links Diabetes to Increased Blood Cancer Risk

By BiotechDaily International staff writers
Posted on 21 Jun 2012
According to a new, worldwide meta-analysis, patients with type 2 diabetes have a significantly increased risk of developing certain types of blood cancers.

A collaborative study led by researchers at The Miriam Hospital (Providence, RI, USA) analyzed 26 (13 case-control and 13 cohort) published observational studies that had evaluated the association between diabetes mellitus type 2 and the incidence of lymphoma, leukemia, and myeloma. The meta-analysis included more than 17,000 cases of type 2 diabetes and blood cancer worldwide. The researchers concluded that patients with type 2 diabetes have about 20% increased risk of developing leukemia, myeloma, and non-Hodgkin lymphoma, as well as a subtype of non-Hodgkin lymphoma known as peripheral T-cell lymphoma. They did not find any associations with Hodgkin lymphoma. The findings suggest type 2 diabetes could be associated with approximately 5% of all incidents of leukemia, myeloma, and non-Hodgkin lymphoma.

The researchers also found that the risk of lymphoma, leukemia, and myeloma appears to differ depending on the geographic region of the original report. For example, the risk of non-Hodgkin lymphoma was higher in Asia and Europe, while there was an increased leukemia risk in the United States and Asia.

“When you consider that [millions of people have type 2 diabetes and that millions more are still likely to develop it], a 20% increased risk of blood cancer is quite significant,” noted lead author Jorge Castillo, MD, a hematologist-oncologist with The Miriam Hospital. He added, “It’s important to remember that type 2 diabetes can, to some degree, be prevented and controlled through lifestyle modification, such as diet and exercise; so by preventing the onset of type 2 diabetes, we could also prevent blood cancer.” Dr. Castillo and colleagues suggested that, in addition to studying antidiabetic therapy, future research should focus particularly on evaluating roles of behavioral factors such as obesity, physical activity, dietary habits, and smoking, which have been linked to both diabetes and cancer.

The findings, published online May 24, 2012, in the American Society of Hematology journal Blood, add to the growing evidence base linking diabetes and certain types of cancer.

Related Links:

The Miriam Hospital



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.